2X Oncology completes series Seed round of $3.5 million.
2X Oncology is a clinical stage biotechnology company focused on developing precision therapeutics for unmet needs in women’s cancers. 2X Oncology has identified and in-licensed three novel anti-cancer drugs that have achieved encouraging levels of partial response rates in phase 1/2 clinical trials.
These drugs will be further developed using their RNA based proprietary biomarker technology, the DRP™ platform, for delivering precision oncology. This identifies the patients that have the highest likelihood of responding to a certain drug, thus ensuring better efficacy outcomes for individual cancer patients.
DRP™ has been extensively validated in its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients.
Copenhagen Life Science Advisors acted as strategic and financial advisor to 2X Oncology Inc.
Zoetis Acquires Scandinavian Micro Biodevices (SMB) to Extend Its Pipeline in Diagnostics for Veterinary Use.
Zoetis has purchased a pioneer in developing and manufacturing microfluidic “lab on a chip” diagnostics for veterinary point-of-care services for $80 million. This adds to the existing diagnostics portfolio with specialty test instruments and cartridges as well as provides a pipeline of next-generation diagnostics to help veterinarians better detect, prevent and treat disease.
Managing Partner of Copenhagen Life Science Advisors has been closely involved in the process leading up to the Zoetis acquisition through his role as chairman of SMB.
Jefferies International Limited acted as sole financial adviser to SMB.
IT company EG A/S acquires e-mergency / welfare solutions and rethinks elderly and social IT solutions. With this acquisition EG takes a decisive step towards creating a common solution within welfare provisions to municipalities in Denmark.
Copenhagen Life Science Advisors acted as advisor for e-mergency.
See press release (in Danish) via following links.
Managing Partner Copenhagen Life Science Advisors, Jarne Elleholm, reports for MedWatch from the annual J. P. Morgan conference in San Francisco.
(Articles in Danish)